Longitude (Cayman)’s Novo Nordisk NVO Stock Holding History

Longitude (Cayman)’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.16M	Buy	45,000 +3,000	+7%	+$129K	0.69%	35
2026 Q1	$1.54M	Buy	42,000 +9,000	+27%	+$426K	0.63%	35
2025 Q4	$1.68M	Buy	+33,000	New	+$1.69M	0.73%	31

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Longitude (Cayman)'s NVO Position: Q2 2026 in Review

Longitude (Cayman) increased its Novo Nordisk (NVO) stake by 7.1% in Q2 2026, buying an estimated $129K and bringing the position to 45,000 shares worth $2.16M. The position accounts for 0.69% of the portfolio, ranked #35.

Longitude (Cayman) first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Longitude (Cayman) held 45,000 shares of Novo Nordisk worth $2.16M as of Q2 2026.
Longitude (Cayman) bought 3,000 Novo Nordisk shares in Q2 2026, an estimated $129K.
Novo Nordisk made up 0.69% of Longitude (Cayman)'s portfolio in Q2 2026, its #35 holding.
Longitude (Cayman) first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Longitude (Cayman)'s 13F filing for Q2 2026, filed 12 Aug 2026.